Intellectual Property,Examined.
An intelligence platform for patent commercialization, tech transfer, evidence, and enforcement readiness. Helix finds who may already be using your patented technology, and where it could be licensed — with the evidence organized for your team to review.
Bring in your portfolio
Patents are added and organized in a workspace your team controls.
See what's out there
Companies, products, and markets surfaced from public sources.
Review the evidence
Source-linked findings prepared for attorney and licensing review.
Decide with a document
Counsel packets, commercialization reports, and executive briefs you can hand off.
Built to move portfolios from raw patents to reviewable decisions.
Most portfolios are
underexamined.
- 01Patents sit unexamined while the market moves.
- 02Potential use is discovered years late, if at all.
- 03Opportunity assessment doesn't scale past a handful of assets.
- 04The evidence that would support either path is scattered across research nobody can retrace.
Two questions.
One portfolio.
Who may already be using this — and who should be paying to. Helix answers both from the same portfolio, with the same evidence discipline behind each answer.
Patent Intelligence
Surface potential patent-use candidates and organize the evidence behind them for attorney review.
- Candidate companies and products identified from public sources
- Claim-level evidence organized element by element, with citations traceable to their source
- Investigation, evidence review, case, and counsel workflows in one place
- Continuous monitoring as new activity appears
Helix prepares candidates and evidence for qualified human review. It does not determine infringement.
- Example candidate 1candidate
- Example candidate 2candidate
- Example candidate 3candidate
- Example candidate 4candidate
- Example candidate 5candidate
Gaps are shown as gaps. When the evidence doesn't support a candidate, Helix says so instead of advancing it.
Commercialization Intelligence
Turn a portfolio into a prioritized list of markets, companies, and licensing paths.
- Potential markets, companies, products, and licensing partners identified per asset
- Opportunities prioritized so teams know what to work on first
- Executive decision briefs with supporting evidence attached
- Ongoing monitoring and reporting as the landscape shifts
Opportunities are candidates for commercial follow-up, not valuations or guarantees of revenue.
- 01Meridian SurgicalInterventional devicesLicensing partner
- 02Northwind RoboticsIndustrial automationProduct overlap
- 03Calyx DiagnosticsPoint-of-care testingMarket entry
- 04Orbital MaterialsAdvanced coatingsPartnership
- 05Ardent MobilityFleet telematicsLicensing partner
Ordered, not just listed. Teams see what to work on first, and the evidence that put it there.
From a portfolio of noise,a reviewable candidate emerges.
The same discipline,
either path.
Every finding links to the source it came from, so a reviewer can open the underlying material and judge it directly.
Each finding carries a stated confidence level and the reason behind it, so reviewers can agree or disagree on the record.
Helix organizes and prioritizes. Your attorneys and licensing team decide.
Monitoring continues after the first pass and flags what changed, so a portfolio stays current without being re-run by hand.
Counsel packets and executive briefs export as finished documents your team can circulate as-is.
Where Helix fits in your work.
Helix sits before the decision. It does the research, organizes the evidence, and hands your team something reviewable — so attorneys and licensing leads spend their time deciding, not searching.
One workspace.
Every step of the work.
Discovery, evidence review, decisions, and reporting live in the same place — so nothing has to be rebuilt in a spreadsheet.
What Helix
delivers.
Work in Helix ends as a document someone can act on — reviewed, sourced, and ready to circulate.
A single document per candidate: the claim elements, the evidence organized against each one, the sources behind it, and the open questions.
- Claim-element evidence
- Source citations
- Open questions and gaps
- PDF export
Markets, companies, products, and licensing paths for an asset or a whole portfolio, ordered by what deserves attention first.
- Markets and companies
- Licensing pathways
- Prioritized shortlist
- PDF export
The short version for people who will not read the file: what was found, how strong it is, and what the recommended next step is.
- Summary of findings
- Confidence and rationale
- Recommended next step
- PDF export
Helix is built for the teams responsible for what a portfolio is worth — the people who decide what to review, what to license, and what to leave alone.
Patent Holders.
Inventors and assignees of the underlying right.
Your portfolio
stays yours.
Each organization works in an isolated workspace. Access is role-controlled, and findings, evidence, and reports are visible only to the people you authorize.
Each organization works in its own workspace. Nothing is shared across tenants.
Access is granted by role, so people see the surfaces their work requires.
Findings, evidence, and reports are visible only to the people you authorize.
Helix is available to a limited number of organizations during closed beta.
See what your portfolio already knows.
Helix is available to a limited number of organizations during closed beta.